Literature DB >> 14600008

Risk factors for Clostridium difficile colonisation and toxin production.

John M Starr1, Heather Martin, Jodie McCoubrey, Gavin Gibson, Ian R Poxton.   

Abstract

OBJECTIVES: to examine risk factors for patients becoming Clostridium difficile culture and toxin positive.
DESIGN: prospective cohort study.
SETTING: two medicine for the elderly wards. PARTICIPANTS: patients admitted to the wards over a 17-month period. MEASUREMENT: presence of Clostridium difficile on culture of stool specimens and toxins A and/or B. Patient's age, sex, source of admission, antibiotic, laxative, antacid and steroid use, presence/absence of colonic disease, neoplasia, leukaemia and nasogastric or percutaneous endoscopic gastrostomy tube feeding.
RESULTS: 390 of 865 patients admitted provided a total of 1003 faecal specimens. Age (OR 1.04, 95% CI 1.001-1.07 per year), admission from another hospital (OR 2.13, 95% CI 1.29-3.50), non-cephalosporin antibiotics (OR 2.08, 95% CI 1.25-3.46) and cephalosporin use (OR 8.45, 95% CI 2.99-23.9) increased risk of becoming Clostridium difficile culture positive. Becoming toxin-positive was associated with antibiotic use only (OR 3.02, 95% CI 1.15-7.92), specifically amoxycillin (OR 8.72, 95% CI 1.66-45.9) and cephalosporins other than ceftriaxone (OR 7.28, 95% CI 1.34-39.6).
CONCLUSION: different risk factors are important for the two stages leading to Clostridium difficile diarrhoea. Age, source of admission and third generation cephalosporins increase risk of becoming culture positive, whilst only antibiotic use is associated with the step of becoming toxin-positive. Understanding these differential risks may aid infection control strategies.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14600008     DOI: 10.1093/ageing/afg112

Source DB:  PubMed          Journal:  Age Ageing        ISSN: 0002-0729            Impact factor:   10.668


  8 in total

Review 1.  Clostridium difficile associated diarrhoea: diagnosis and treatment.

Authors:  John Starr
Journal:  BMJ       Date:  2005-09-03

2.  Quasiexperimental study of the effects of antibiotic use, gastric acid-suppressive agents, and infection control practices on the incidence of Clostridium difficile-associated diarrhea in hospitalized patients.

Authors:  Mamoon A Aldeyab; Stephan Harbarth; Nathalie Vernaz; Mary P Kearney; Michael G Scott; Chris Funston; Karen Savage; Denise Kelly; Motasem A Aldiab; James C McElnay
Journal:  Antimicrob Agents Chemother       Date:  2009-03-16       Impact factor: 5.191

3.  Risk Factors for the Development of Clostridium difficile-associated Colitis after Colorectal Cancer Surgery.

Authors:  Chang Ho Yeom; Min Mi Cho; Seong Kyu Baek; Ok Suk Bae
Journal:  J Korean Soc Coloproctol       Date:  2010-10-31

4.  Structure and function of a Clostridium difficile sortase enzyme.

Authors:  Christopher J Chambers; April K Roberts; Clifford C Shone; K Ravi Acharya
Journal:  Sci Rep       Date:  2015-03-24       Impact factor: 4.379

5.  Asymptomatic and yet C. difficile-toxin positive? Prevalence and risk factors of carriers of toxigenic Clostridium difficile among geriatric in-patients.

Authors:  Klaus Nissle; Daniel Kopf; Alexander Rösler
Journal:  BMC Geriatr       Date:  2016-11-15       Impact factor: 3.921

6.  Frequency of Clostridium difficile among patients with gastrointestinal complaints.

Authors:  Ehsan Nazemalhosseini-Mojarad; Masoumeh Azimirad; Maryam Razaghi; Parisa Torabi; Ali Moosavi; Masoud Alebouyeh; Mohammad Mehdi Aslani; Mohammad Reza Zali
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2011

7.  Nosocomial transmission of C. difficile in English hospitals from patients with symptomatic infection.

Authors:  Esther van Kleef; Antonio Gasparrini; Rebecca Guy; Barry Cookson; Russell Hope; Mark Jit; Julie V Robotham; Sarah R Deeny; W John Edmunds
Journal:  PLoS One       Date:  2014-06-16       Impact factor: 3.240

8.  Antibiotic overuse in older patients: an important clinical reminder of pseudomembranous colitis.

Authors:  C M H Pinxt; R M M Bogie; N M J Hanssen; B Spaetgens
Journal:  QJM       Date:  2021-12-20
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.